Sugi Predict

Sugi Predict / Compounds / SCHEMBL1841353

SCHEMBL1841353

SCHEMBL1841353

Cc1c([C@@H](C)NC(=O)c2ccc3nc(C(C)(O)C(F)(F)F)ccc3c2)cnn1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRPF1 P55201 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ KMT2A Q03164 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ DDR2 Q16832 3/20 0.35
▸ CYP17A1 P05093 2/20 0.34
▸ NR1I2 O75469 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ LMNA P02545 1/20 0.33
▸ GFER P55789 1/20 0.33
▸ CDK2 P24941 1/20 0.33
▸ AKT1 P31749 1/20 0.33
▸ KCNT1 Q5JUK3 2/20 0.33
▸ CYP3A4 P08684 1/20 0.32
▸ MAOB P27338 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1838653 1.00 BRPF1 (0.51) BRPF1KDM4EALDH1A1MAPTKMT2A
SCHEMBL12571642 0.93 BRPF1 (0.51) BRPF1KDM4EALDH1A1MAPTKMT2A
SCHEMBL1842642 0.91 BRPF1 (0.54) BRPF1KDM4EALDH1A1MAPTKMT2A
SCHEMBL1844278 0.91 BRPF1 (0.54) BRPF1KDM4EALDH1A1MAPTKMT2A
SCHEMBL1839961 0.87 BRPF1 (0.51) BRPF1KDM4EALDH1A1MAPTKMT2A
SCHEMBL1841666 0.87 BRPF1 (0.51) BRPF1KDM4EALDH1A1MAPTKMT2A
SCHEMBL2008903 0.87 BRPF1 (0.51) BRPF1KDM4EALDH1A1MAPTKMT2A
SCHEMBL1839524 0.87 BRPF1 (0.51) BRPF1KDM4EALDH1A1MAPTKMT2A
SCHEMBL1843752 0.82 BRPF1 (0.41) BRPF1DDR2CYP2C9CDK2AKT1
SCHEMBL1841106 0.82 BRPF1 (0.41) BRPF1DDR2CYP2C9CDK2AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964732-B2 Substituted bicyclocarboxyamide compounds PFIZER INC. (US) 2011-06-21 — — US disclosed
US-7964732-B2 Substituted bicyclocarboxyamide compounds PFIZER INC. (US) 2011-06-21 — — US disclosed
EP-2091944-B1 SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS PFIZER (US) 2011-05-18 — — EP disclosed
EP-2091944-B1 SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS PFIZER (US) 2011-05-18 — — EP disclosed
US-20100267769-A1 Substituted Bicyclocarboxyamide Compounds Pfizer, Inc. and Renovis Inc. 2010-10-21 — — US disclosed
US-20100267769-A1 Substituted Bicyclocarboxyamide Compounds Pfizer, Inc. and Renovis Inc. 2010-10-21 — — US disclosed
WO-2008059370-A2 SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS PFIZER JAPAN INC. (JP) 2008-05-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267769-A1 Substituted Bicyclocarboxyamide Compounds TRPV1, OPRL1, CNR1 BRPF1 1691/4885KDM4E 4164/4885ALDH1A1 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.